Henriksen Magne, Jahnsen Jørgen, Lygren Idar, Aadland Erling, Schulz Tom, Vatn Morten H, Moum Bjørn
Department of Internal Medicine, Østfold Hospital Moss, and Aker University Hospital, Oslo, Norway.
Scand J Gastroenterol. 2007 May;42(5):602-10. doi: 10.1080/00365520601076124.
There are few population-based, prospective studies on the clinical course in patients with Crohn's disease (CD).
To extend the observation period in a population-based prospective study (the IBSEN study) to find out more about the initial 5-year clinical course in CD patients and to relate the findings to the Vienna classification.
All patients diagnosed with inflammatory bowel disease (IBD) in southeastern Norway in the 4 years 1990-1993 were followed prospectively. The patients were invited to a systematic follow-up visit at their local hospital 1 and 5 years after inclusion in the study. The visits included a structured interview, a clinical examination and colonoscopy.
Out of 843 patients initially diagnosed with IBD, 200 patients with definite CD were alive and had sufficient data for analysis 5 years after diagnosis. Changes in disease localization and behaviour in relation to the Vienna classification were observed in 27 (13.5%) and 35 patients (17.5%), respectively. During the observation period, 56 patients (28%) underwent surgery with intestinal resection, and half of these had disease localized in the terminal ileum. At the time of the 5-year visit, oral sulfasalazin and 5-aminosalicylic acid (5-ASA) were the most frequently used medications (by 54% of the patients), while oral glucocorticosteroids and azathioprine were being used by 25% and 13%, respectively. Seventy-two percent of the patients had taken oral glucocorticosteroids at some time in the course of the 5-year period. The majority of the patients had intestinal symptoms at 5 years, but only 16% had symptoms that interfered with everyday activities. Fourteen percent of the patients had had a relapse-free 5-year course; however, relapse was not related to the initial Vienna classification. When the patients described the clinical course, 44% reported an improvement in symptoms during the follow-up period.
The 5-year clinical course in an unselected cohort of CD patients was mostly mild. The frequency of surgery was lower than that observed in other studies and only a minority of the patients had symptoms that interfered with everyday activities 5 years after the initial diagnosis. The Vienna classification predicted the risk of surgery, but did not predict symptoms at 5 years, relapses during the observation period or the course of disease as described by the patients.
关于克罗恩病(CD)患者临床病程的基于人群的前瞻性研究较少。
在一项基于人群的前瞻性研究(IBSEN研究)中延长观察期,以更深入了解CD患者最初5年的临床病程,并将研究结果与维也纳分类法相关联。
对1990 - 1993年4年间在挪威东南部被诊断为炎症性肠病(IBD)的所有患者进行前瞻性随访。患者在纳入研究后的1年和5年被邀请到当地医院进行系统的随访。随访包括结构化访谈、临床检查和结肠镜检查。
在最初诊断为IBD的843例患者中,200例确诊为CD的患者在诊断后5年仍然存活且有足够的数据用于分析。分别在27例(13.5%)和35例(17.5%)患者中观察到疾病定位和行为与维也纳分类法相关的变化。在观察期内,56例(28%)患者接受了肠切除术,其中一半患者的病变位于回肠末端。在5年随访时,口服柳氮磺胺吡啶和5 - 氨基水杨酸(5 - ASA)是最常用的药物(54%的患者使用),而口服糖皮质激素和硫唑嘌呤的使用比例分别为25%和13%。72%的患者在5年期间的某个时间服用过口服糖皮质激素。大多数患者在5年时仍有肠道症状,但只有16%的患者症状影响日常活动。14%的患者有5年无复发病程;然而,复发与最初的维也纳分类法无关。当患者描述临床病程时,44%的患者报告在随访期间症状有所改善。
未经选择的CD患者队列的5年临床病程大多较为轻微。手术频率低于其他研究中观察到的频率,且只有少数患者在最初诊断5年后出现影响日常活动的症状。维也纳分类法可预测手术风险,但不能预测5年时的症状、观察期内的复发情况或患者描述的疾病病程。